Aging is a complex process that can lead to chronic diseases such as diabetes, cardiovascular disorders, muscular degeneration, atherosclerosis and neurodegeneration, and it is currently one of the major scientific concerns in the field of medicine [1].
Several strategies have been developed to date for the promotion of healthy aging and an increase in the duration of life. One of the recent strategies that can decrease the deleterious impact of aging and increase the regenerative property at the cellular level is cellular reprogramming.
Cellular reprogramming can convert a somatic cell into an induced pluripotent stem cell (iPSC). It not only helps to restore tissue and organ function but also helps to determine cell fate. This, in turn, helps in the maintenance of cellular identity through the expression of cell type-specific genes and suppression of lineage-inappropriate genes [2].
A bit concerning cellular reprogramming after a few minutes, and stating a goal just before 7:00 a stated goal of reversing aging across the entire human.
“There are no hard limits imposed by biology or by physics that says that we can’t live better longer,” Kristen Fortney, CEO of San Francisco-based BioAge Labs, told the outlet. Focused on discerning the markers of aging, BioAge Labs is using large amounts of biobank blood and tissue samples to do so.
The company has already found a drug target that slows aging-linked muscle loss in mice.
“There is a protein called apelin that circulates in the blood, and we saw that middle-aged people with higher levels of apelin in their blood were living longer, with better muscle function and better cognitive function as they age,” Fortney said, according to Express.
A new study in an animal model of aging indicates a potential reason for why women who have early menopause or other genetic conditions affecting the reproductive system are more prone to develop cardiovascular disease, diabetes, and dementia.
The new study, led by researchers from the University of Pittsburgh and UPMC and published in the journal Aging Cell, found that disrupting a process called meiosis in C. elegans reproductive cells caused a decline in the worms’ health and triggered an accelerated aging gene signature similar to that of aging humans.
“This study is exciting because it’s the first direct evidence that manipulating the health of reproductive cells leads to premature aging and a decline in healthspan,” said senior author Arjumand Ghazi, Ph.D., associate professor of pediatrics, developmental biology, and cell biology and physiology at Pitt and UPMC Children’s Hospital of Pittsburgh. “The implications of this finding are profound: It suggests that the status of the reproductive system is important not simply to produce children, but also for overall health.”
People affected by the lethal glioblastoma cancer only live for 12–18 months after diagnosis.
A global trial that began in 2007 has confirmed that a vaccine for the treatment of the most lethal brain cancer can give patients years of extended life.
Glioblastoma is not only the most common form of brain cancer but is also one of the deadliest. People affected by the disease only live just 12–18 months after the diagnosis, or even less.
Now, thanks to the vaccine DCVax, some 2,500 people who are diagnosed with deadly cancer in the UK could be benefitted.
Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.
This is primarily about Rejuvant or AKG trials. When they first reported an 8 year age difference I did not truly believe it as that would mean I could take it, de-age, then age a bit, then just take it again. The tests however are ongoing and will feature people who are biologically older than their calendar age. There is also mention of 110 drugs/supplements that do “something” to mice. That would be quite a stack to take.
Dr Brian Kennedy presents potential interventions for extend our healthspan. Among them, Rejuvant – a CaAKG supplement which contain calcium + alpha-ketoglutarate shows better response for people who has biological age older than chronological age.
The first human trial of Rejuvant to reverse human biological age by 8 years in 7 month.
Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660611/
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, and preventing human aging and associated diseases. He is a Professor in the Departments of Biochemistry and Physiology at National University Singapore and Director of the Centre for Healthy Ageing in the National University Health System. From 2010 to 2016 he was the President and CEO of the Buck Institute for Research on Aging. Currently, he remains as a Professor at the Institute. Dr. Kennedy also has an adjunct appointment at the USC Davis School of Gerontology. Dr. Kennedy is also actively involved Biotechnology companies, serving in consulting and Board capacities, as well as Scientific Director of Affirmativ Health. Dr. Kennedy also serves as a Co-Editor-In-Chief at Aging Cell.
Advancing Novel Therapeutic Interventions For Unmet Medical Needs — Dr. Michael Hufford, Ph.D., Co-Founder and CEO, LyGenesis; Interim CEO, Morphoceuticals; Scientific Advisor, Juvenescence.
Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis (https://www.lygenesis.com/), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals (https://www.morphoceuticals.com/) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected.
Dr. Hufford also serves as a scientific advisor to Juvenescence (https://juvlabs.com/) a biotech holding company that develops therapies and products to modify aging and help people live longer.
An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has designed and executed clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatric and oncology indications. His experience in-and out-licensing pre-clinical and clinical stage assets, executing corporate partnering deals, and in investor relations, has helped him to raise public, private, and angel-back financing for his companies. His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, Inc. (https://www.harmreductiontherapeutics.org/), a nonprofit pharmaceutical company developing low-cost over-the-counter intra-nasal naloxone in the US to help prevent opioid overdose deaths.
Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh, before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.
The maniacally focused founder of Insilico Medicine is going all in on AI to discover new medicines and extend lifespan.
But researchers are now using artificial intelligence to accelerate parts of that process by orders of magnitude. The same kind of technology that recognizes your face or autocompletes your emails can potentially add years to your life, experts say.
